ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

SANDOSTATIN
Cytoprotective and supportive care agents
Pituitary disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

SANDOSTATIN Rx

Generic Name and Formulations:
Octreotide acetate 50mcg, 100mcg, 500mcg; per vial; soln for IV or SC inj; contains mannitol, phenol.

Company:
Novartis Pharmaceuticals Corp

Therapeutic Use:

Indications for SANDOSTATIN:

Severe diarrhea and flushing due to metastatic carcinoid tumors. Profuse watery diarrhea due to vasoactive intestinal peptide-secreting tumors (VIPomas).

Adult:

Give by IV infusion over 15–30 minutes, IV push over 3 minutes, or deep SC (intrafat) inj. Carcinoid tumors: 100–600mcg/day in 2–4 divided doses for first 2 weeks; usual maintenance: 450mcg/day; max 1500mcg/day. VIPomas: Initially 200–300mcg/day in 2–4 divided doses for first 2 weeks; max 750mcg/day.

Children:

Not recommended.

Warnings/Precautions:

Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Carcinoid tumors: monitor 5-HIAA, plasma serotonin, plasma Substance P. VIPomas: perform baseline and periodic total and/or free T4 measurements with chronic therapy. Monitor thyroid function, gallbladder, glucose, vitamin B12. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.

See Also:

SANDOSTATIN LAR DEPOT

Pharmacological Class:

Somatostatin analogue.

Adverse Reactions:

Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, injection site pain, headache, dizziness, pancreatitis, altered dietary fat absorption.

How Supplied:

Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10; LAR kit—1 (5mL vial w. supplies)

Indications for SANDOSTATIN:

Acromegaly unresponsive to or that cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.

Adult:

Give by IV infusion over 15–30 minutes, IV push over 3 minutes, or deep SC (intrafat) inj. Initially 50mcg 3 times daily. Usual maintenance: 100micrograms 3 times daily; max 500mcg 3 times daily. Reevaluate every 6 months. Pituitary irradiation recipients: withdraw therapy for 4 weeks once yearly to assess disease activity; resume if GH or IGF-1 levels increase or signs/symptoms recur.

Children:

Not recommended.

Warnings/Precautions:

Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Monitor growth hormone, IGF-1 levels, thyroid function, gallbladder, glucose, vitamin B12. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.

See Also:

SANDOSTATIN LAR DEPOT

Pharmacological Class:

Somatostatin analogue.

Adverse Reactions:

Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, injection site pain, headache, dizziness, pancreatitis, altered dietary fat absorption.

How Supplied:

Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10; LAR kit—1 (5mL vial w. supplies)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs